NEUROONE MEDICAL TECHNOLOGIE
NMTCNASDAQTrading Snapshot
- Day Range
- $0.85 – $0.93
- 52-Week Range
- $0.77 – $6.12
- Volume (shares)
- 35,804
- Avg Volume (shares)
- —
- Shares Outstanding
- 9.1M
- Next Earnings
- 2027-02-15
Fundamentals Snapshot
- Annual Revenue
- $12M
- Last Q Revenue
- $2M
- P/E Ratio
- -0.9
- P/S Ratio
- 0.8x
- EPS (TTM)
- $-0.83
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +63.0%
NEUROONE MEDICAL TECHNOLOGIE
NMTC
StockOtter · stockotter.spaceAbout NEUROONE MEDICAL TECHNOLOGIE
NeuroOne Medical Technologies Corporation functions as a specialized medical technology enterprise. Its core mission involves the invention and market deployment of sophisticated thin-film electrode systems. These systems are crafted for diverse neurophysiological applications, such as the continuous recording of electroencephalograms (cEEG) and stereoelectroencephalograms (sEEG), as well as therapeutic interventions including spinal cord stimulation, brain stimulation, and ablation procedures. The technology aims to assist individuals afflicted by conditions like epilepsy, Parkinson's disease, dystonia, essential tremors, persistent pain arising from unsuccessful back surgeries, and a variety of other neurological disorders. Furthermore, the company has forged a crucial partnership with RBC Medical Innovations to engineer a radio frequency ablation generator. This generator is designed to integrate seamlessly with NeuroOne's unique dual-function electrode, allowing for both the precise monitoring of brain electrical activity and the targeted ablation of brain tissue using a singular instrument. The corporate headquarters are situated in Eden Prairie, Minnesota.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
ⓘLatest News & Updates
NeuroOne Featured in New York Post on OneRF® Patient's Remarkable Journey to Overcome Debilitating Facial Pain
NeuroOne's FDA 510(k)-Cleared OneRF Trigeminal Nerve Ablation System Offers Hope for Patients Suffering from Trigeminal Neuralgia EDEN PRAIRIE, Minn., Oct. 27, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corpo
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Company's Research Program
NeuroOne Secures First Pharmaceutical Industry Purchase Order for StereoCED™ Drug Delivery Platform to Support Tier 1 Global Pharmaceutical Research
NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Stock Short Interest Climbs 135.8%
NeuroOne Medical Technologies Corporation (NASDAQ: NMTC - Get Free Report) was the recipient of a significant increase in short interest in the month of September. As of September 30th, there was short interest totaling
NeuroOne® Joins Dartmouth-Led Research Team on $1 Million NIH Grant to Advance Neurotransmitter Sensing Technology
New NIH Award will Initially Provide NeuroOne Approximately $200,000 through April 2027 EDEN PRAIRIE, Minn., Oct. 08, 2026 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “
NeuroOne (NASDAQ: NMTC) secures a $4.5M order as revenue climbs again
What happened NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) said preliminary fourth-quarter product revenue was $3.8 million. That was up 38.4% from $2.7 million a year earlier. The company also said full-year
NeuroOne Reports Preliminary Fiscal Q4 Product Revenue Growth of 38.4%; Secures Record $4.5 Million Purchase Order
Preliminary Fiscal Q4 2026 Product Revenue of $3.8 Million Preliminary Full-Year Product Revenue Up 15.6% to $10.5 Million, at the Top of Guidance Range EDEN PRAIRIE, Minn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- NeuroOne Med